Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
bioRxiv ; 2022 Jan 25.
Article in English | MEDLINE | ID: mdl-35018378

ABSTRACT

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infections result in the temporary loss of smell and taste (anosmia and dysgeusia) in about one third of confirmed cases. Several investigators have reported that the viral spike protein receptor is present in olfactory neurons. However, no study has been published to date showing the presence of viral entry sites angiotensin-converting enzyme 2 (ACE2), neuropilin1 (NRP1), and TMPRSS2, the serine protease necessary for priming the viral proteins, in human nerves that are responsible for taste sensation (cranial nerves: VII, IX and X). We used immunocytochemistry to examine three postmortem donor samples of the IXth (glossopharyngeal) and Xth (vagal) cranial nerves where they leave/join the medulla from three donors to confirm the presence of ACE2, NRP1 and TMPRSS2. Two samples were paraffin embedded; one was a frozen sample. In addition to staining sections from the latter, we isolated RNA from it, made cDNA, and performed PCR to confirm the presence of the mRNAs that encode the proteins visualized. All three of the proteins required for SARS-CoV-2 infections appear to be present in the human IXth and Xth nerves near the medulla. Direct infection of these nerves by the COVID-19 virus is likely to cause the loss of taste experienced by many patients. In addition, potential viral spread through these nerves into the adjacent brainstem respiratory centers might also aggravate the respiratory problems patients are experiencing.

2.
Neuroscience ; 163(1): 233-43, 2009 Sep 29.
Article in English | MEDLINE | ID: mdl-19481589

ABSTRACT

The cytokine transforming growth factor alpha (TGF alpha) has proangiogenic and proneurogenic effects and can potentially reduce infarct volumes. Therefore, we administered TGF alpha or vehicle directly into the area surrounding the infarct in female mice that received gender-mismatched bone marrow transplants from green fluorescent protein (GFP)-expressing males prior to undergoing permanent middle cerebral artery occlusion. Newborn cells were tracked with bromodeoxyuridine (BrdU) labeling and immunohistochemistry at 90 days after stroke onset. We also studied the ingress of bone marrow-derived cells into the ischemic brain to determine whether such cells contribute to angiogenesis or neurogenesis. Infarct volumes were measured at 90 days poststroke. The results show that TGF alpha led to significant increments in the number of newborn neurons and glia in the ischemic hemisphere. TGF alpha also led to significant increments in the number of bone marrow-derived cells entering into the ischemic hemisphere. Most of these cells did not label with BrdU and represented endothelial cells that incorporated into blood vessels in the infarct border zone. Our results also show that infarct size was significantly reduced in animals treated with TGF alpha compared with controls. These results suggest that TGF alpha can induce angiogenesis, neurogenesis and neuroprotection after stroke. At least part of the pro-angiogenic effect appears to be secondary to the incorporation of bone marrow-derived endothelial cells into blood vessels in the infarct border zone.


Subject(s)
Neovascularization, Physiologic/drug effects , Nerve Regeneration/physiology , Neurogenesis/drug effects , Stroke/drug therapy , Transforming Growth Factor alpha/therapeutic use , Animals , Bone Marrow Transplantation/methods , Cell Differentiation/physiology , Cell Movement/drug effects , Cell Movement/physiology , Disease Models, Animal , Endothelial Cells/drug effects , Endothelial Cells/physiology , Endothelial Cells/transplantation , Female , Graft Survival/physiology , Green Fluorescent Proteins , Male , Mice , Mice, Inbred C57BL , Nerve Regeneration/drug effects , Neuroglia/cytology , Neuroglia/drug effects , Neuroglia/physiology , Neurons/cytology , Neurons/drug effects , Neurons/physiology , Recovery of Function/drug effects , Stroke/physiopathology , Stroke/surgery , Treatment Outcome
3.
Mol Psychiatry ; 13(5): 498-506, 2008 May.
Article in English | MEDLINE | ID: mdl-17622221

ABSTRACT

Considerable attention has focused on regulation of central tryptophan hydroxylase (TPH) activity and protein expression. At the time of these earlier studies, it was thought that there was a single central TPH isoform. However, with the recent identification of TPH2, it becomes important to distinguish between regulatory effects on the protein expression and activity of the two isoforms. We have generated a TPH2-specific polyclonal antiserum (TPH2-6361) to study regulation of TPH2 at the protein level and to examine the distribution of TPH2 expression in rodent and human brain. TPH2 immunoreactivity (IR) was detected throughout the raphe nuclei, in lateral hypothalamic nuclei and in the pineal body of rodent and human brain. In addition, a prominent TPH2-IR fiber network was found in the human median eminence. We recently reported that glucocorticoid treatment of C57/Bl6 mice for 4 days markedly decreased TPH2 messenger RNA levels in the raphe nuclei, whereas TPH1 mRNA was unaffected. The glucocorticoid-elicited inhibition of TPH2 gene expression was blocked by co-administration of the glucocorticoid receptor antagonist mifepristone (RU-486). Using TPH2-6361, we have extended these findings to show a dose-dependent decrease in raphe TPH2 protein levels in response to 4 days of treatment with dexamethasone; this effect was blocked by co-administration of mifepristone. Moreover, the glucocorticoid-elicited inhibition of TPH2 was functionally significant: serotonin synthesis was significantly reduced in the frontal cortex of glucocorticoid-treated mice, an effect that was blocked by mifepristone co-administration. This study provides further evidence for the glucocorticoid regulation of serotonin biosynthesis via inhibition of TPH2 expression, and suggest that elevated glucocorticoid levels may be relevant to the etiology of psychiatric diseases, such as depression, where hypothalamic-pituitary-adrenal axis dysregulation has been documented.


Subject(s)
5-Hydroxytryptophan/biosynthesis , Dexamethasone/analogs & derivatives , Frontal Lobe/chemistry , Nerve Tissue Proteins/biosynthesis , Raphe Nuclei/enzymology , Tryptophan Hydroxylase/analysis , Tryptophan Hydroxylase/biosynthesis , 5-Hydroxytryptophan/analysis , Amino Acid Sequence , Animals , Antibody Specificity , Dexamethasone/pharmacology , Enzyme Induction/drug effects , Female , Frontal Lobe/drug effects , Humans , Immune Sera , Mice , Mice, Inbred C57BL , Mifepristone/pharmacology , Molecular Sequence Data , Nerve Tissue Proteins/analysis , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/immunology , Ovariectomy , Peptide Fragments/immunology , Protein Isoforms/biosynthesis , Protein Isoforms/genetics , Protein Isoforms/immunology , RNA, Messenger/biosynthesis , Raphe Nuclei/drug effects , Rats , Rats, Sprague-Dawley , Tryptophan Hydroxylase/genetics , Tryptophan Hydroxylase/immunology
4.
J Physiol Paris ; 95(1-6): 147-51, 2001.
Article in English | MEDLINE | ID: mdl-11595429

ABSTRACT

BACKGROUND: Recently we demonstrated that gastric mucosa of rats can synthesize, store and release dopamine. Out of five different subtypes, mRNA of D5 (=D1b) dopamine receptor is very abundant in the gastric epithelium. D1 receptor selective dopamine agonists have been shown to protect against experimental gastro-duodenal lesions. AIMS: To test the hypothesis that protective effects of dopamine involve D5 receptors, mucosal lesions were induced in D5 receptor deficient (KO) and wild-type (WT) mice using cysteamine. Morphology and gastric acid secretion of D5 KO mice were also studied. METHODS: Single doses of 600 mg/kg, 300 mg/kg cysteamine or vehicle were administered subcutaneously to fasted animals. After 24 h, number and severity of gastro-duodenal lesions were analyzed. Basal and histamine-induced maximal gastric acid output were measured by a stomach-sac wash-through method. RESULTS: All the KOs in the 600 mg/kg cysteamine group died within 4 h showing symptoms of toxicity while three out of four WTs survived (P<0.05). Mortality after 300 mg/kg cysteamine was significantly higher in KOs versus the WTs: 6/14 versus 2/11, P<0.05. Gastric lesion-index was also significantly higher in KOs (median, middle quartile): four (3-9) versus 0 (0-0), P<0.05. Duodenal lesions did not develop from this single dose of cysteamine in either genotype. Basal and histamine-induced maximal gastric acid output were comparable in the two genotypes. CONCLUSIONS: This study demonstrates that loss of D5 receptor causes mucosal vulnerability and increased toxicity of cysteamine in genetically manipulated mice. Thus, D5 receptor subtype is indeed likely to be involved in protective effects of dopamine in the stomach.


Subject(s)
Cysteamine/pharmacology , Cytoprotection/physiology , Receptors, Dopamine D1/physiology , Animals , Gastric Acid/metabolism , Gastric Mucosa/drug effects , Gastric Mucosa/pathology , Immunohistochemistry , Male , Mice , Mice, Knockout/genetics , Receptors, Dopamine D1/deficiency , Receptors, Dopamine D1/genetics , Receptors, Dopamine D5 , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...